Skip to main content

Global Custom Antibody Market grows 10% CAGR through biomarker discovery and drug innovation 2030

 


The custom antibody market is set to witness a CAGR of ~10% during the forecast period. The market growth is primarily driven by expanding R&D activities, increasing demand for customized antibodies, growing adoption of targeted therapeutics, and advancements in antibody engineering and production technologies. However, the high costs associated with development and the time-intensive nature of antibody generation present challenges that may slow market adoption. 

Custom antibodies are indispensable tools used by researchers and clinicians in life science research, medicine and diagnostics. These antibodies are designed in laboratories to identify and target a specific antigen of interest with high accuracy and precision that may not be addressed by commercially available antibodies. Antigen synthesis, serum collection, animal immunization (usually in rabbits, mice, or goats), and purification are some of the procedures which are used to produce custom antibodies.

Download a free sample report now 👉
https://meditechinsights.com/custom-antibody-market/request-sample/

Targeted therapeutics drive growth in the custom antibody market

The key factor propelling the custom antibody market growth is the increasing demand for precision medicine and targeted therapeutics. With the growing number of R&D activities and better understanding of the molecular basis of complex diseases like cancer, autoimmune disorders, and infectious diseases, researchers need highly specific antibodies to identify and manipulate disease-related proteins. For instance, in June 2025, BioNTech and Bristol Myers Squibb signed a global collaboration to co-develop and co-commercialize BNT327, BioNTech’s PD‑L1 × VEGF‑A next-generation bispecific antibody for multiple solid tumor types.

Custom antibodies have a specific ability to bind precisely to unique epitopes, which can improve the detection in diagnostics and enhance efficacy in therapeutic applications. Additionally, biotech and pharma companies are investing more in custom antibody production to support the development of ADCs (antibody-drug conjugates) and other advanced biologics. For example, in December 2022, Merck announced an exclusive license and collaboration agreement with Kelun-Biotech to co-develop seven investigational preclinical antibody-drug conjugates (ADCs) for cancer treatment. This trend not only fuels market demand but also expands the applications of custom antibodies.

Technological innovations and collaborations boost custom antibody efficiency

In the evolving landscape of biotechnology, custom antibodies have emerged as an invaluable tool, propelling technological advancements in the diagnostic and therapeutic areas. One such notable innovation is the use of custom antibodies in phage display technology. This method allows scientists to rapidly screen billions of antibody variants and identify those with optimal binding to a specific target antigen.

Unlike other methods, this method has gained widespread adoption in industry and academic research, as it enhances the speed, scalability, and ability to produce tailored antibodies, which are significant for therapeutic applications. For instance,

  • In December 2024, Antibody Solutions received approval to become a CRO for Levena’s Singularity™ SAPIEN™ Mouse platform, a transgenic animal model which allows researchers to generate high-affinity, human-derived antibodies more efficiently for both therapeutic and diagnostic applications
  • In March 2024, Sino Biological, Inc. announced a collaboration with Rapid Novor, Inc. Under this agreement, Sino Biological leveraged Rapid Novors' REmAb monoclonal antibody (mAb) sequencing platform alongside its custom antibody development and production services, providing a seamless pipeline from antibody discovery to delivery

The increasing collaborations among biotech companies and research organizations has improve antibody performance and making the development process more efficient and reproducible. With the growing number of technological innovations, the barrier to entry for high-quality custom antibody production is being lowered, making it more accessible for a broader range of users in the research and diagnostics field.

Competitive Landscape Analysis

The global custom antibody market is marked by the presence of established and emerging market players such as Thermo Fisher Scientific Inc.; Abcam plc; Bio-Rad Laboratories, Inc; Creative Biolabs; Merck KGaA; Agilent Technologies Inc; GenScript; Laboratory Corporation of America; Danaher Corporation; Kaneka Eurogentec S.A.; Bio-Techne; and Sino Biological, Inc., among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

 Download a sample report for in-depth competitive insights
https://meditechinsights.com/custom-antibody-market/request-sample/

Global Custom Antibody Market Segmentation

This report by Medi-Tech Insights provides the size of the global custom antibody market at the regional- and country-level from 2023 to 2030. The report further segments the market based on type, service, source, application, and end-user.

Market Size & Forecast (2023-2030), By Type, USD Million

  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Recombinant Antibodies
  • Others

Market Size & Forecast (2023-2030), By Service, USD Million

  • Antibody Development
  • Antibody Production & Purification
  • Antibody Fragmentation & Labelling

Market Size & Forecast (2023-2030), By Source, USD Million

  • Mice
  • Rabbit
  • Others

Market Size & Forecast (2023-2030), By Application, USD Million

  • Oncology
  • Infectious Diseases
  • Neurology
  • Stem cells
  • Immunology
  • Cardiovascular Diseases
  • Others

Market Size & Forecast (2023-2030), By End-user, USD Million

  • Hospitals & Clinics
  • Academic & Research Institutes
  • CRO
  • Others

Market Size & Forecast (2023-2030), By Region, USD Million

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde
Associate, Medi-Tech Insights
 +32 498 86 80 79
 info@meditechinsights.com 

Comments

Post a Comment

Popular posts from this blog

Global Biotechnology Market to grow at 13–15% CAGR as CRISPR use expands globally by 2029

  The global biotechnology market is set to witness a growth rate of 13-15% in the next 5 years.  Advancements in genetic engineering and genomics; growing demand for biopharmaceuticals; rising incidence of chronic diseases; growth in environmental and agricultural biotechnology; increased investment in R&D; growing demand for synthetic biology; and presence of favorable government initiatives are some of the key factors driving the biotechnology market. Biotechnology is the scientific field that uses biological organisms, systems, or processes to develop products and technologies aimed at improving health, agriculture, environmental sustainability, and industrial efficiency. By applying principles of genetics, molecular biology, and biochemistry, biotechnology enables advancements like genetic engineering, biopharmaceutical development, biofuels, and genetically modified organisms (GMOs). This field is instrumental in producing therapies for diseases, increasing crop r...
Post a Comment
Read more

Global Multi Cancer Early Detection Market expanding 15–20% CAGR through personalized care 2030

  The multi cancer early detection market is expected to grow at a CAGR of around 15-20% during the forecast period.  This growth is primarily due to the rising awareness and increasing demand for early-stage screening tools, especially as cancer rates continue to rise globally, and technological advancements in screening methods. However, high costs and strict regulations can still hinder the market growth.  Multi Cancer Early Detection (MCED) refers to tests designed to detect multiple cancers, often from a single blood sample, unlike traditional methods, which can include multiple diagnostic tests or biopsies. These tests look for signs like DNA methylation patterns or small traces of tumor DNA floating in the bloodstream. The primary goal is early cancer detection, ideally before any symptoms appear, so the overall treatment is more effective and less expensive. Download a free sample report now 👉 https://meditechinsights.com/multi-cancer-early-detection-marke...
Post a Comment
Read more

Global Structural Heart Devices Market growth 9% CAGR with favorable reimbursement scenarios 2030

  The global structural heart devices market is set to witness a CAGR of ~9% in the next 5 years.  The rising geriatric population & corresponding rise in the prevalence of heart disease, technological advancements in structural heart devices, regulatory approval for expanded indications for several transcatheter heart valves, and increasing awareness and favorable reimbursements for these procedures in key markets are some of the pivotal factors driving the growth of the structural heart devices market. However, high device costs, complex procedures, and stringent regulatory hurdles continue to restrain market uptake.  Structural heart disease occurs when something is wrong with one’s heart valves, walls, chambers or muscles. It exists from birth or develops as one age. It includes conditions such as congenital heart disease, cardiomyopathy, and heart valve disease. Heart valve devices, occluders & delivery systems, annuloplasty rings, heart access systems, cl...
Post a Comment
Read more